58 results
8-K
EX-1.1
ANNX
Annexon Inc
7 Jun 24
Annexon Announces Pricing of $125 Million Underwritten Public Offering
4:42pm
or access to the IT Assets and Confidential Data, except as described in the Registration Statement and the Prospectus or except as would not reasonably … , access, misappropriation or modification (collectively, with the Privacy Laws, the “Data Protection Requirements”). Except as would not, individually
8-K
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
was conducted in Bangladesh and Philippines due to the high prevalence of GBS and limited access to standard of care intravenous immunoglobulin. Based
8-K
EX-99.2
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
Conducted in Bangladesh and Philippines given high prevalence of GBS of all types, scientific leadership in GBS, and limited access to IVIg KEY ENDPOINTS
8-K
EX-99.1
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
prevalence of GBS and limited access to standard of care intravenous immunoglobulin (IVIg). Based on feedback from the FDA, Annexon has initiated a real … . Participants can use guest dial-in numbers above and be answered by an operator or they can click the Call me™ link for instant telephone access to the event
8-K
EX-99.1
67hs0r0q lkhbrs
4 Mar 24
Regulation FD Disclosure
5:25pm
8-K
EX-1.1
gyrqz
21 Dec 23
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
4:09pm
424B5
j2990fi6ff4jf3w7coy
21 Dec 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-10.1
0k62a8dj9mia
8 Jul 22
Annexon Announces $130 Million Private Placement Financing
5:19pm